Does the media refer more to ELVN or LXRX?

In the previous week, Lexicon Pharmaceuticals had 15 more articles in the media than Enliven Therapeutics. MarketBeat recorded 19 mentions for Lexicon Pharmaceuticals and 4 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 1.12 beat Lexicon Pharmaceuticals' score of 0.34 indicating that Enliven Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lexicon Pharmaceuticals 4 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer LXRX or AMLX?

In the previous week, Lexicon Pharmaceuticals had 15 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 19 mentions for Lexicon Pharmaceuticals and 4 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 0.99 beat Lexicon Pharmaceuticals' score of 0.34 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexicon Pharmaceuticals 4 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Amylyx Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LXRX or GRAL?

In the previous week, Lexicon Pharmaceuticals had 9 more articles in the media than GRAIL. MarketBeat recorded 19 mentions for Lexicon Pharmaceuticals and 10 mentions for GRAIL. GRAIL's average media sentiment score of 0.60 beat Lexicon Pharmaceuticals' score of 0.34 indicating that GRAIL is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexicon Pharmaceuticals 4 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral GRAIL 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LEGN or LXRX?

In the previous week, Lexicon Pharmaceuticals had 12 more articles in the media than Legend Biotech. MarketBeat recorded 19 mentions for Lexicon Pharmaceuticals and 7 mentions for Legend Biotech. Lexicon Pharmaceuticals' average media sentiment score of 0.34 beat Legend Biotech's score of 0.33 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lexicon Pharmaceuticals 4 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to VKTX or LXRX?

In the previous week, Viking Therapeutics had 2 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 21 mentions for Viking Therapeutics and 19 mentions for Lexicon Pharmaceuticals. Viking Therapeutics' average media sentiment score of 0.60 beat Lexicon Pharmaceuticals' score of 0.34 indicating that Viking Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 10 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lexicon Pharmaceuticals 4 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Lexicon Pharmaceuticals (LXRX) Competitors

$1.82 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.84 +0.01 (+0.82%)

As of 07:30 PM Eastern

Compare

LXRX vs. ELVN, AMLX, GRAL, LEGN, and VKTX

Should you buy Lexicon Pharmaceuticals stock or one of its competitors? Lexicon Pharmaceuticals's main competitors and comparable companies include Enliven Therapeutics (ELVN), Amylyx Pharmaceuticals (AMLX), GRAIL (GRAL), Legend Biotech (LEGN), and Viking Therapeutics (VKTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Lexicon Pharmaceuticals compare to Enliven Therapeutics?

Enliven Therapeutics (NASDAQ:ELVN) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Enliven Therapeutics has a net margin of 0.00% compared to Lexicon Pharmaceuticals' net margin of -147.38%. Enliven Therapeutics' return on equity of -18.55% beat Lexicon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-18.55%	-18.09%
Lexicon Pharmaceuticals	-147.38%	-37.53%	-24.96%

Lexicon Pharmaceuticals has higher revenue and earnings than Enliven Therapeutics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A
Lexicon Pharmaceuticals	$49.80M	16.13	-$50.34M	-$0.15	N/A

Enliven Therapeutics currently has a consensus price target of $74.44, indicating a potential upside of 59.41%. Lexicon Pharmaceuticals has a consensus price target of $5.70, indicating a potential upside of 215.79%. Given Lexicon Pharmaceuticals' higher possible upside, analysts clearly believe Lexicon Pharmaceuticals is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Lexicon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

95.1% of Enliven Therapeutics shares are owned by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. 3.0% of Enliven Therapeutics shares are owned by company insiders. Comparatively, 14.0% of Lexicon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Lexicon Pharmaceuticals had 15 more articles in the media than Enliven Therapeutics. MarketBeat recorded 19 mentions for Lexicon Pharmaceuticals and 4 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 1.12 beat Lexicon Pharmaceuticals' score of 0.34 indicating that Enliven Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enliven Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lexicon Pharmaceuticals	4 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Enliven Therapeutics has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market. Comparatively, Lexicon Pharmaceuticals has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market.

Summary

Lexicon Pharmaceuticals beats Enliven Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Lexicon Pharmaceuticals compare to Amylyx Pharmaceuticals?

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. 14.0% of Lexicon Pharmaceuticals shares are held by insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Amylyx Pharmaceuticals has a net margin of 0.00% compared to Lexicon Pharmaceuticals' net margin of -147.38%. Lexicon Pharmaceuticals' return on equity of -37.53% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexicon Pharmaceuticals	-147.38%	-37.53%	-24.96%
Amylyx Pharmaceuticals	N/A	-52.92%	-48.53%

Lexicon Pharmaceuticals presently has a consensus price target of $5.70, indicating a potential upside of 215.79%. Amylyx Pharmaceuticals has a consensus price target of $38.86, indicating a potential upside of 38.15%. Given Lexicon Pharmaceuticals' higher probable upside, equities analysts clearly believe Lexicon Pharmaceuticals is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexicon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00

Lexicon Pharmaceuticals has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.1, meaning that its share price is 110% less volatile than the broader market.

Lexicon Pharmaceuticals has higher earnings, but lower revenue than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexicon Pharmaceuticals	$49.80M	16.13	-$50.34M	-$0.15	N/A
Amylyx Pharmaceuticals	$87.37M	35.87	-$144.74M	-$1.43	N/A

In the previous week, Lexicon Pharmaceuticals had 15 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 19 mentions for Lexicon Pharmaceuticals and 4 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 0.99 beat Lexicon Pharmaceuticals' score of 0.34 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexicon Pharmaceuticals	4 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amylyx Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Lexicon Pharmaceuticals beats Amylyx Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Lexicon Pharmaceuticals compare to GRAIL?

Lexicon Pharmaceuticals (NASDAQ:LXRX) and GRAIL (NASDAQ:GRAL) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.

74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. 14.0% of Lexicon Pharmaceuticals shares are owned by insiders. Comparatively, 1.8% of GRAIL shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Lexicon Pharmaceuticals has a net margin of -147.38% compared to GRAIL's net margin of -236.95%. GRAIL's return on equity of -15.88% beat Lexicon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexicon Pharmaceuticals	-147.38%	-37.53%	-24.96%
GRAIL	-236.95%	-15.88%	-14.02%

Lexicon Pharmaceuticals has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market. Comparatively, GRAIL has a beta of 2.81, suggesting that its share price is 181% more volatile than the broader market.

Lexicon Pharmaceuticals presently has a consensus price target of $5.70, indicating a potential upside of 215.79%. GRAIL has a consensus price target of $93.60, indicating a potential downside of 32.71%. Given Lexicon Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Lexicon Pharmaceuticals is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexicon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
GRAIL	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

Lexicon Pharmaceuticals has higher earnings, but lower revenue than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexicon Pharmaceuticals	$49.80M	16.13	-$50.34M	-$0.15	N/A
GRAIL	$147.17M	42.22	-$408.35M	-$9.75	N/A

In the previous week, Lexicon Pharmaceuticals had 9 more articles in the media than GRAIL. MarketBeat recorded 19 mentions for Lexicon Pharmaceuticals and 10 mentions for GRAIL. GRAIL's average media sentiment score of 0.60 beat Lexicon Pharmaceuticals' score of 0.34 indicating that GRAIL is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexicon Pharmaceuticals	4 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
GRAIL	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Lexicon Pharmaceuticals beats GRAIL on 9 of the 16 factors compared between the two stocks.

How does Lexicon Pharmaceuticals compare to Legend Biotech?

Legend Biotech (NASDAQ:LEGN) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

Legend Biotech currently has a consensus price target of $55.79, indicating a potential upside of 196.91%. Lexicon Pharmaceuticals has a consensus price target of $5.70, indicating a potential upside of 215.79%. Given Lexicon Pharmaceuticals' higher probable upside, analysts clearly believe Lexicon Pharmaceuticals is more favorable than Legend Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.53
Lexicon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

70.9% of Legend Biotech shares are owned by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. 0.0% of Legend Biotech shares are owned by insiders. Comparatively, 14.0% of Lexicon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Legend Biotech has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market. Comparatively, Lexicon Pharmaceuticals has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market.

Lexicon Pharmaceuticals has lower revenue, but higher earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.03B	3.54	-$296.80M	-$0.25	N/A
Lexicon Pharmaceuticals	$49.80M	16.13	-$50.34M	-$0.15	N/A

Legend Biotech has a net margin of -7.21% compared to Lexicon Pharmaceuticals' net margin of -147.38%. Legend Biotech's return on equity of -8.71% beat Lexicon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-7.21%	-8.71%	-5.40%
Lexicon Pharmaceuticals	-147.38%	-37.53%	-24.96%

In the previous week, Lexicon Pharmaceuticals had 12 more articles in the media than Legend Biotech. MarketBeat recorded 19 mentions for Lexicon Pharmaceuticals and 7 mentions for Legend Biotech. Lexicon Pharmaceuticals' average media sentiment score of 0.34 beat Legend Biotech's score of 0.33 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Legend Biotech	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lexicon Pharmaceuticals	4 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Lexicon Pharmaceuticals beats Legend Biotech on 10 of the 16 factors compared between the two stocks.

How does Lexicon Pharmaceuticals compare to Viking Therapeutics?

Viking Therapeutics (NASDAQ:VKTX) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.

In the previous week, Viking Therapeutics had 2 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 21 mentions for Viking Therapeutics and 19 mentions for Lexicon Pharmaceuticals. Viking Therapeutics' average media sentiment score of 0.60 beat Lexicon Pharmaceuticals' score of 0.34 indicating that Viking Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	10 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lexicon Pharmaceuticals	4 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

76.0% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. 5.3% of Viking Therapeutics shares are owned by company insiders. Comparatively, 14.0% of Lexicon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Lexicon Pharmaceuticals has higher revenue and earnings than Viking Therapeutics. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A
Lexicon Pharmaceuticals	$49.80M	16.13	-$50.34M	-$0.15	N/A

Viking Therapeutics has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market. Comparatively, Lexicon Pharmaceuticals has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market.

Viking Therapeutics currently has a consensus target price of $99.67, suggesting a potential upside of 230.57%. Lexicon Pharmaceuticals has a consensus target price of $5.70, suggesting a potential upside of 215.79%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Viking Therapeutics is more favorable than Lexicon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Lexicon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Viking Therapeutics has a net margin of 0.00% compared to Lexicon Pharmaceuticals' net margin of -147.38%. Lexicon Pharmaceuticals' return on equity of -37.53% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-94.56%	-82.75%
Lexicon Pharmaceuticals	-147.38%	-37.53%	-24.96%

Summary

Viking Therapeutics beats Lexicon Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Lexicon Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LXRX vs. The Competition

Export

Metric	Lexicon Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$809.82M	$3.87B	$7.14B	$13.10B
Dividend Yield	N/A	3.65%	2.54%	16.76%
P/E Ratio	-12.13	7.65	214.49	21.54
Price / Sales	16.26	1,292.25	607.75	91.81
Price / Cash	N/A	122.60	77.60	51.75
Price / Book	6.07	16.63	10.92	6.30
Net Income	-$50.34M	-$22.67M	$3.50B	$361.43M
7 Day Performance	1.39%	-3.05%	-2.11%	-1.67%
1 Month Performance	-18.75%	-10.75%	-6.34%	-3.94%
1 Year Performance	31.88%	21.11%	8.81%	2.77%

Lexicon Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LXRX Lexicon Pharmaceuticals	1.9258 of 5 stars	$1.82 flat	$5.70 +213.2%	+29.1%	$809.82M	$49.80M	N/A	81
ELVN Enliven Therapeutics	2.873 of 5 stars	$48.87 -1.2%	$75.00 +53.5%	+133.0%	$3.62B	N/A	N/A	67	Positive News Analyst Forecast Gap Up
AMLX Amylyx Pharmaceuticals	3.5892 of 5 stars	$32.39 -0.1%	$38.86 +20.0%	+100.6%	$3.61B	$87.37M	N/A	136	News Coverage
GRAL GRAIL	1.0473 of 5 stars	$107.97 +33.7%	$70.30 -34.9%	+113.6%	$3.61B	$147.17M	N/A	910	Analyst Forecast High Trading Volume
LEGN Legend Biotech	3.5538 of 5 stars	$18.53 +5.2%	$53.14 +186.8%	-40.8%	$3.41B	$1.03B	N/A	2,965	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LXRX) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lexicon Pharmaceuticals (LXRX) Competitors

LXRX vs. ELVN, AMLX, GRAL, LEGN, and VKTX

How does Lexicon Pharmaceuticals compare to Enliven Therapeutics?

Summary

How does Lexicon Pharmaceuticals compare to Amylyx Pharmaceuticals?

Summary

How does Lexicon Pharmaceuticals compare to GRAIL?

Summary

How does Lexicon Pharmaceuticals compare to Legend Biotech?

Summary

How does Lexicon Pharmaceuticals compare to Viking Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXRX vs. The Competition

Lexicon Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lexicon Pharmaceuticals (LXRX) Competitors

LXRX vs. ELVN, AMLX, GRAL, LEGN, and VKTX

How does Lexicon Pharmaceuticals compare to Enliven Therapeutics?

Is ELVN or LXRX more profitable?

Which has higher earnings and valuation, ELVN or LXRX?

Do analysts prefer ELVN or LXRX?

Do institutionals & insiders believe in ELVN or LXRX?

Does the media refer more to ELVN or LXRX?

Which has more risk and volatility, ELVN or LXRX?

Summary

How does Lexicon Pharmaceuticals compare to Amylyx Pharmaceuticals?

Do institutionals and insiders believe in LXRX or AMLX?

Is LXRX or AMLX more profitable?

Do analysts recommend LXRX or AMLX?

Which has more volatility & risk, LXRX or AMLX?

Which has preferable valuation & earnings, LXRX or AMLX?

Does the media prefer LXRX or AMLX?

Summary

How does Lexicon Pharmaceuticals compare to GRAIL?

Do institutionals and insiders believe in LXRX or GRAL?

Is LXRX or GRAL more profitable?

Which has more risk & volatility, LXRX or GRAL?

Do analysts prefer LXRX or GRAL?

Which has preferable earnings and valuation, LXRX or GRAL?

Does the media prefer LXRX or GRAL?

Summary

How does Lexicon Pharmaceuticals compare to Legend Biotech?

Do analysts prefer LEGN or LXRX?

Do institutionals and insiders believe in LEGN or LXRX?

Which has more volatility and risk, LEGN or LXRX?

Which has better earnings & valuation, LEGN or LXRX?

Is LEGN or LXRX more profitable?

Does the media prefer LEGN or LXRX?

Summary

How does Lexicon Pharmaceuticals compare to Viking Therapeutics?

Does the media refer more to VKTX or LXRX?

Do insiders & institutionals hold more shares of VKTX or LXRX?

Which has better valuation and earnings, VKTX or LXRX?

Which has more risk & volatility, VKTX or LXRX?

Do analysts recommend VKTX or LXRX?

Is VKTX or LXRX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXRX vs. The Competition

Lexicon Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools